Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05340335
Other study ID # S2021-2407-0002
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date April 18, 2022
Est. completion date May 2, 2022

Study information

Verified date July 2022
Source Asan Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Currently used drugs for monitored general anesthesia include propofol, midazolam, and dexmedetomidine. Each drug has different advantages and disadvantages. Remimazolam causes a relatively small decrease in blood pressure, and it has no injection pain. In addition, remimazolam has a very short onset time, and even after the continuous infusion, the onset of remimazolam is fast, and even after continuous injection, the effect disappeared very quickly due to the short context-sensitive half time. nd through continuous infusion, the patient's depth of anesthesia can be maintained constant. In addition, the short duration of action and the ability to quickly reverse the effect of flumazenil suggest that remimazolam can be used effectively under general anesthesia as well as under general anesthesia. Remimazolam can be used as a continuous infusion for general anesthesia. However, it has also been reported to be used for sedation by continuous infusion or divided intravenous infusion. However, the effective infusion dose of remimazolam for supervised general anesthesia without mechanical ventilation has not been established. In this study, the ED90 of the loading dose to induce loss of consciousness in patients when supervised general anesthesia is performed through continuous infusion of Remimazolam is to be obtained.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date May 2, 2022
Est. primary completion date May 2, 2022
Accepts healthy volunteers No
Gender All
Age group 19 Years to 80 Years
Eligibility Inclusion Criteria: - ASA PS 1-3 - Patients who are scheduled to undergo upper/lower limb surgery under the monitored anesthetic care with remimazolam Exclusion Criteria: - Patients who refuse to participate in this study - Patients with hypersensitivity to benzodiazepine or flumazenil - Patients with severe renal/hepatic disease - Patients with drug/alcohol abuse - Patients who take antidepressants, anticonvulsants, psychoactive drugs chronically - Patients with difficulty in communication - Patients with severe obstructive sleep apnea or other airway problems - Patients contraindicated to regional anesthesia - Patients judged to be inappropriate for this study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Remimazolam
A beginning dose of remimazolam is 1mg/kg/hr. When sedation is not achieved in 10 minutes, the dose will be increased by 0.1mg/kg/hr in the next patient. When sedation is successful, the same dose will be used with the probability of 0.89, or the dose will be decreased by 0.1mg/kg/hr with the probability of 0.11 in the next patient. (maximal dose: 2mg/kg/hr)

Locations

Country Name City State
Korea, Republic of Asan Medical Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Asan Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Whether sedation was successful MOAA/S score of 3 or less (MOAA/S: Modified Observer's Alertness/Sedation scale) Awake (5) - Unresponsive (0) for 10 minutes from the initiation of the remimazolam administration
Secondary Total amount of remimazolam for sedation MOAA/S score of 3 or less From the initiation of the remimazolam administration to the time when MOAA/S score of 3 or less, assessed up to 10 minutes
Secondary Effect site concentration Calculated by a computerized program(Asanpump) From the initiation of the remimazolam administration to the time when MOAA/S score of 3 or less, assessed up to 10 minutes
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05512559 - Body Composition Analysis and Time to Emergence From Remimazolam
Recruiting NCT05939674 - Effects of Flumazenil on Recovery After Total Intravenous Anesthesia With Remimazolam N/A
Recruiting NCT05856617 - Remimazolam vs Propofol as an Induction Agent for Morbid Obesity Patients Phase 4
Recruiting NCT05533580 - Differential Effects of Remimazolam and Propofol on Dynamic Cerebral Autoregulation During General Anesthesia N/A
Recruiting NCT05533567 - Electroencephalographic Profiles During General Anesthesia: a Comparative Study of Remimazolam and Propofol N/A
Completed NCT05320016 - Effects of Remimazolam on Quality of Recovery After Ambulatory Surgery
Not yet recruiting NCT06427785 - The Effect of Wavelet Index in Monitoring the Sedation Depth of Remimazolam Besylate
Completed NCT05379777 - Effective Dose of Remimazolam for Sedation in Patients Undergoing Lower Extremity Surgery Under Spinal Anesthesia Phase 4
Recruiting NCT06398275 - Remimazolam for Emergence Delirium Prevention in Patients Undergoing Rhinoseptoplasty, FESS or Septoplasty Phase 2
Not yet recruiting NCT06275594 - Trial Evaluating the Efficacy of Remimazolam in Endobronchial Ultrasound Guided Transbronchial Needle Aspiration Phase 2
Recruiting NCT05864625 - Comparison of Hemodynamic Stability During Anesthesia Using Remimazolam and Sevoflurane in Minimally Invasive AVR N/A
Recruiting NCT05907525 - Effect of Sevoflurane and Remimazolam on Arterial Oxygenation During One-lung Ventilation N/A
Completed NCT05322902 - Remimazolam Total Intravenous Anesthesia Under Analgesia Nociception Index-guidance N/A
Recruiting NCT06009991 - The Dose Range of Remimazolam Besylate in Different Age Groups N/A
Not yet recruiting NCT05432050 - Bispectral Index and Patient State Index During General Anesthesia With Remimazolam
Not yet recruiting NCT05434494 - The Effect of Remifentanil on ED95 of Remimazolam for Loss of Consciousness in Adult Patients N/A
Completed NCT05688345 - Comparison of Recovery Profiles Among Propofol, Remimazolam, and Dexmedetomidine After Intraoperative Sedation Phase 4
Recruiting NCT05891145 - Remimazolam for Postoperative Atrial Fibrillation N/A
Recruiting NCT05651399 - Comparison in Frequency of Hypotension Between Remimazolam and Propofol in Hip Surgery Phase 4
Completed NCT05527314 - Effect of Remimazolam vs Sevoflurane Anesthesia on Incidence of Emergence Agitation and Complications in Children Undergoing Ophthalmic Surgery N/A